BR112015008155A2 - combinações - Google Patents

combinações

Info

Publication number
BR112015008155A2
BR112015008155A2 BR112015008155A BR112015008155A BR112015008155A2 BR 112015008155 A2 BR112015008155 A2 BR 112015008155A2 BR 112015008155 A BR112015008155 A BR 112015008155A BR 112015008155 A BR112015008155 A BR 112015008155A BR 112015008155 A2 BR112015008155 A2 BR 112015008155A2
Authority
BR
Brazil
Prior art keywords
amino
human
pharmaceutically acceptable
acceptable salt
combinations
Prior art date
Application number
BR112015008155A
Other languages
English (en)
Portuguese (pt)
Inventor
Robert Auger Kurt
Gopal Reddy Peddareddigari Vijay
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of BR112015008155A2 publication Critical patent/BR112015008155A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112015008155A 2012-10-12 2013-10-10 combinações BR112015008155A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261712869P 2012-10-12 2012-10-12
US201361833561P 2013-06-11 2013-06-11
PCT/US2013/064260 WO2014059095A1 (en) 2012-10-12 2013-10-10 Combinations

Publications (1)

Publication Number Publication Date
BR112015008155A2 true BR112015008155A2 (pt) 2017-07-04

Family

ID=50477878

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015008155A BR112015008155A2 (pt) 2012-10-12 2013-10-10 combinações

Country Status (11)

Country Link
US (1) US20160263116A1 (cg-RX-API-DMAC7.html)
EP (1) EP2906215A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015533165A (cg-RX-API-DMAC7.html)
KR (1) KR20150067323A (cg-RX-API-DMAC7.html)
CN (1) CN104755079A (cg-RX-API-DMAC7.html)
AU (1) AU2013329199A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015008155A2 (cg-RX-API-DMAC7.html)
CA (1) CA2888094A1 (cg-RX-API-DMAC7.html)
IN (1) IN2015DN02667A (cg-RX-API-DMAC7.html)
RU (1) RU2015117483A (cg-RX-API-DMAC7.html)
WO (1) WO2014059095A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2779975T3 (es) 2014-02-07 2020-08-21 Verastem Inc Métodos y composiciones para tratar el crecimiento celular anormal
GB201510628D0 (en) * 2015-06-17 2015-07-29 Glaxosmithkline Ip No 2 Ltd Novel use
WO2021047783A1 (en) 2019-09-13 2021-03-18 The Institute Of Cancer Research: Royal Cancer Hospital Vs-6063 in combination with ch5126766 for the treatment of cancer
AU2021253243B2 (en) * 2020-04-08 2024-01-18 Aptabio Therapeutics Inc. Agent for treating contrast-induced acute kidney injury
US11873296B2 (en) 2022-06-07 2024-01-16 Verastem, Inc. Solid forms of a dual RAF/MEK inhibitor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104382906A (zh) * 2009-11-17 2015-03-04 葛兰素史密斯克莱有限责任公司 药物组合
WO2012045194A1 (en) * 2010-10-09 2012-04-12 Abbott Laboratories Benzodiazepinones as fak inhibitors for treatment of cancer
AU2012209100A1 (en) * 2011-01-26 2013-08-01 Board Of Regents The University Of Texas System Combinations

Also Published As

Publication number Publication date
JP2015533165A (ja) 2015-11-19
AU2013329199A1 (en) 2015-04-16
US20160263116A1 (en) 2016-09-15
CA2888094A1 (en) 2014-04-17
RU2015117483A (ru) 2016-12-10
KR20150067323A (ko) 2015-06-17
EP2906215A1 (en) 2015-08-19
IN2015DN02667A (cg-RX-API-DMAC7.html) 2015-09-04
CN104755079A (zh) 2015-07-01
EP2906215A4 (en) 2016-05-18
WO2014059095A1 (en) 2014-04-17

Similar Documents

Publication Publication Date Title
DOP2017000105A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
EA201491299A1 (ru) Карбаматные соединения, их получение и применение
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
BR112015007778A2 (pt) profármacos neutralizantes de vegf para o tratamento de condições oculares
BR112015000150A2 (pt) composições farmacêuticas dissuasoras de abuso de liberação controlada
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
MX382516B (es) Composiciones y metodos para absorcion transmucosa.
CL2012002192A1 (es) Sal de metilnaltrexona cuyo anión es un excipiente anfifílico; composición farmacéutica para administración oral que comprende esta sal y un excipiente anfifílico; método de preparación de la composición farmaceutica; método para reducir efectos secundarios de la terapia opioide; producto; y paquete multidía.
HK1223304A1 (zh) 包含二甲双胍和二氢槲皮素的药物组合及其用於治疗癌症的用途
MX2015002005A (es) Combinacion de inhibidor de p13k e inhibidor de c-met.
BR112012024887A2 (pt) grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção
MD20150057A2 (ro) Compoziţie farmaceutică cu conţinut de hidroclorură de nalbufină, utilizarea ei pentru tratamentul sindromului algic de intensitate medie şi înaltă şi metodă de obţinere a compoziţiei farmaceutice
MX2015013148A (es) Nuevos compuestos de bencensulfonamida, metodo para sintetizar los mismos, y uso de los mismos en medicina asi como tambien en cosmeticos.
EA201391027A1 (ru) Комбинация
PH12015500653A1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
BR112013019775A2 (pt) composto, composição farmacêutica e método para tratar declínio cognitivo ou doença de alzheimer em um paciente
EA201390345A1 (ru) Терапевтическое болеутоляющее средство
BR102012028120B8 (pt) Uso de um ou mais derivados de ingenol, composição farmacêutica e medicamento
IN2015DN02667A (cg-RX-API-DMAC7.html)
BR112013018296A2 (pt) tratamento de disfunções cognitivas em esquizofrenia
PE20151424A1 (es) Compuesto farmaceutico para la prevencion y el tratamiento de un trastorno o una enfermedad cognitivos, neurodegenerativos o neuronales
ES2469240B1 (es) Uso de un agente fotosensible capaz de producir especies reactivas de oxígeno en la preparación de un medicamento útil para la terapia fotodinámica de una enfermedad relacionada con células madre, uso "in vitro" y composición farmacéutica.
EA201270445A1 (ru) Комбинация
EA201391742A1 (ru) Фармацевтическая композиция, включающая фексофенадин
MX2013013574A (es) Composicion farmaceutica que comprende drotaverina.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]